307 related articles for article (PubMed ID: 1283520)
1. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma.
Gill PS; Bernstein-Singer M; Espina BM; Rarick M; Magy F; Montgomery T; Berry MS; Levine A
AIDS; 1992 Dec; 6(12):1477-81. PubMed ID: 1283520
[TBL] [Abstract][Full Text] [Related]
2. AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma.
Gill PS; Mitsuyasu RT; Montgomery T; Huang J; Cabriales S; Testa M; Espina BM; Levine AM; Miles SA
Cancer J Sci Am; 1997; 3(5):278-83. PubMed ID: 9327151
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary Kaposi's sarcoma in AIDS patients treated with combined chemotherapy and recombinant human granulocyte colony-stimulating factor.
Mastroianni A; Coronado O; Cancellieri C; Manfredi R; Pignatari S; Chiodo F
J Chemother; 1998 Oct; 10(5):405-10. PubMed ID: 9822360
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS.
Krown SE; Paredes J; Bundow D; Polsky B; Gold JW; Flomenberg N
J Clin Oncol; 1992 Aug; 10(8):1344-51. PubMed ID: 1634925
[TBL] [Abstract][Full Text] [Related]
5. Phase I AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi's sarcoma.
Gill PS; Miles SA; Mitsuyasu RT; Montgomery T; McCarthy S; Espina BM; Feldstein M; Levine AM
AIDS; 1994 Dec; 8(12):1695-9. PubMed ID: 7534090
[TBL] [Abstract][Full Text] [Related]
6. Treatment of poor prognosis epidemic Kaposi's sarcoma with doxorubicin, bleomycin, vindesine and recombinant human granulocyte-monocyte colony stimulating factor (rh GM-CSF).
Bakker PJ; Danner SA; ten Napel CH; Kroon FP; Sprenger HG; van Leusen R; Meenhorst PL; Muusers A; Veenhof CH
Eur J Cancer; 1995; 31A(2):188-92. PubMed ID: 7536434
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex.
Levine JD; Allan JD; Tessitore JH; Falcone N; Galasso F; Israel RJ; Groopman JE
Blood; 1991 Dec; 78(12):3148-54. PubMed ID: 1742482
[TBL] [Abstract][Full Text] [Related]
8. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial.
Gill PS; Rarick M; McCutchan JA; Slater L; Parker B; Muchmore E; Bernstein-Singer M; Akil B; Espina BM; Krailo M
Am J Med; 1991 Apr; 90(4):427-33. PubMed ID: 1707230
[TBL] [Abstract][Full Text] [Related]
9. GM-CSF as an alternative to dose modification of the combination zidovudine and interferon-alpha in the treatment of AIDS-associated Kaposi's sarcoma.
Scadden DT; Bering HA; Levine JD; Bresnahan J; Evans L; Epstein C; Groopman JE
Am J Clin Oncol; 1991; 14 Suppl 1():S40-4. PubMed ID: 2048563
[TBL] [Abstract][Full Text] [Related]
10. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial.
Kaplan LD; Kahn JO; Crowe S; Northfelt D; Neville P; Grossberg H; Abrams DI; Tracey J; Mills J; Volberding PA
J Clin Oncol; 1991 Jun; 9(6):929-40. PubMed ID: 2033429
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection.
Davey RT; Davey VJ; Metcalf JA; Zurlo JJ; Kovacs JA; Falloon J; Polis MA; Zunich KM; Masur H; Lane HC
J Infect Dis; 1991 Jul; 164(1):43-52. PubMed ID: 1676045
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
Mamounas EP; Anderson S; Wickerham DL; Clark R; Stoller R; Hamm JT; Stewart JA; Bear HD; Glass AG; Bornstein R
Am J Clin Oncol; 1994 Oct; 17(5):374-81; discussion 382. PubMed ID: 7522393
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma.
Scadden DT; Bering HA; Levine JD; Bresnahan J; Evans L; Epstein C; Groopman JE
J Clin Oncol; 1991 May; 9(5):802-8. PubMed ID: 2016623
[TBL] [Abstract][Full Text] [Related]
14. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L; Chow C; Goldspiel B; Cowan KH
Blood; 1995 Oct; 86(8):2913-21. PubMed ID: 7579383
[TBL] [Abstract][Full Text] [Related]
16. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha maintenance therapy after cytotoxic chemotherapy for treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma.
Gill PS; Rarick MU; Bernstein-Singer M; Espina BM; Jones B; Montgomery T; Sharma D; Rasheed S; Levine AM
J Biol Response Mod; 1990 Oct; 9(5):512-6. PubMed ID: 2254762
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
Gill PS; Wernz J; Scadden DT; Cohen P; Mukwaya GM; von Roenn JH; Jacobs M; Kempin S; Silverberg I; Gonzales G; Rarick MU; Myers AM; Shepherd F; Sawka C; Pike MC; Ross ME
J Clin Oncol; 1996 Aug; 14(8):2353-64. PubMed ID: 8708728
[TBL] [Abstract][Full Text] [Related]
19. Experience with adriamycin, bleomycin, vincristine (ABV) palliative chemotherapy in advanced AIDS-related Kaposi's sarcoma.
Paparizos VA; Kyriakis KP; Mileounis KA; Pfandl-Polydorou D; Stavrianeas NG; Vareltzidis AG; Stratigos JD
J Chemother; 1996 Oct; 8(5):403-6. PubMed ID: 8957723
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.
Stewart S; Jablonowski H; Goebel FD; Arasteh K; Spittle M; Rios A; Aboulafia D; Galleshaw J; Dezube BJ
J Clin Oncol; 1998 Feb; 16(2):683-91. PubMed ID: 9469358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
